{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:08:41Z","timestamp":1779188921389,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Coronavirus disease 2019 is a pandemic with no specific therapeutic agents or vaccination. Small published case series on critically ill adults suggest improvements in clinical status with minimal adverse events when patients receive coronavirus disease 2019 convalescent plasma, but data on critically ill pediatric patients are lacking. We report a series of four critically ill pediatric patients with acute respiratory failure who received coronavirus disease 2019 convalescent plasma as a treatment strategy for severe disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case Summary:<\/jats:title>\n            <jats:p>Patients ranged in age from 5 to 16 years old. All patients received coronavirus disease 2019 convalescent plasma within the first 26 hours of hospitalization. Additional disease modifying agents were also used. All patients made a full recovery and were discharged home off of oxygen support. No adverse events occurred from the coronavirus disease 2019 convalescent plasma transfusions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Coronavirus disease 2019 convalescent plasma is a feasible therapy for critically ill pediatric patients infected with severe acute respiratory syndrome coronavirus 2. Well-designed clinical trials are necessary to determine overall safety and efficacy of coronavirus disease 2019 convalescent plasma and additional treatment modalities in pediatric patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000237","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:44:50Z","timestamp":1601599490000},"page":"e0237","source":"Crossref","is-referenced-by-count":8,"title":["Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series"],"prefix":"10.1097","volume":"2","author":[{"given":"Stephanie P.","family":"Schwartz","sequence":"first","affiliation":[{"name":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Lercher","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey A.","family":"Rimland","sequence":"additional","affiliation":[{"name":"Univeristy of North Carolina at Chapel Hill Medical Scientist Training Program, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luther","family":"Bartelt","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara A.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena Janda","family":"Markmann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra","family":"Raut","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmanane","family":"Premkumar","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Kuruc","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Willis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"R1-20231023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R3-20231023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm6914e4","article-title":"Coronavirus disease 2019 in children - United States, February 12-April 2, 2020.","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20231023","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamapediatrics.2020.1467","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review.","volume":"174","author":"Castagnoli","year":"2020","journal-title":"JAMA Pediatr"},{"key":"R5-20231023","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1542\/hpeds.2020-000208","article-title":"COVID-19: A UK children\u2019s hospital experience.","volume":"10","author":"Kanthimathinathan","year":"2020","journal-title":"Hosp Pediatr"},{"key":"R6-20231023","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMc2005073","article-title":"SARS-CoV-2 infection in children.","volume":"382","author":"Lu","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20231023","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpeds.2020.05.007","article-title":"Severe COVID-19 in children and young adults in the Washington, DC metropolitan region.","volume":"233","author":"DeBiasi","year":"2020","journal-title":"J Pediatr"},{"key":"R8-20231023","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection.","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"R9-20231023","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma.","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"R10-20231023","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A rapid review.","volume":"5","author":"Valk","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20231023","doi-asserted-by":"crossref","first-page":"102790","DOI":"10.1016\/j.transci.2020.102790","article-title":"Treatment for emerging viruses: Convalescent plasma and COVID-19.","volume":"59","author":"Brown","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"R12-20231023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tmrv.2020.04.001","article-title":"Convalescent plasma: Therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic.","volume":"34","author":"Sullivan","year":"2020","journal-title":"Transfus Med Rev"},{"key":"R13-20231023","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/S2352-3026(20)30117-4","article-title":"The resurgence of convalescent plasma therapy.","volume":"7","year":"2020","journal-title":"Lancet Haematol"},{"key":"R14-20231023","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.","volume":"92","author":"Ye","year":"2020","journal-title":"J Med Virol"},{"key":"R15-20231023","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients.","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20231023","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea.","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"R17-20231023","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1172\/JCI140200","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients.","volume":"130","author":"Joyner","year":"2020","journal-title":"J Clin Invest"},{"key":"R18-20231023","doi-asserted-by":"crossref","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"R19-20231023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis.","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"R20-20231023","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): A double-blind, randomised, placebo-controlled trial.","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R21-20231023","doi-asserted-by":"crossref","first-page":"m1256","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.","volume":"368","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"R22-20231023","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial.","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"R23-20231023","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.2020.10218","article-title":"A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals.","volume":"324","author":"Casadevall","year":"2020","journal-title":"JAMA"},{"key":"R24-20231023","doi-asserted-by":"crossref","first-page":"102866. [online ahead of print]","DOI":"10.1016\/j.transci.2020.102866","article-title":"First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.","author":"Figlerowicz","year":"2020 Jul 1","journal-title":"Transfus Apher Sci"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T17:06:38Z","timestamp":1698080798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000237","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}